

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical Trial Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPCTA	Independent investigators at all career levels.	• Supports the rapid execution and analysis of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. • Applications cannot support preclinical research. • Preproposal submission is required; application submission is by invitation only. • Clinical Trial Only Option: Applications must include documentation demonstrating U.S. Food and Drug Administration (FDA) or other regulatory approval or exemption to proceed, as applicable. • Clinical Trial with Planning Phase Option: The Planning Phase provides support to prepare and submit an Investigational New Drug or Investigational Device Exemption application to the FDA. Requires FDA or other regulatory approval or exemption to proceed before commencing the clinical trial option. • Funding Levels: Three funding levels are offered with or without a Planning Phase; each funding level describes a defined clinical trial scope: ◦ Funding Level 1: Provides support for a phase 0 or phase 1 clinical trial or non-phased trial with fewer than 100 subjects. ◦ Funding Level 2: Provides support for a phase 2 clinical trial or non-phased trial with fewer than 300 subjects. ◦ Funding Level 3: Provides support for a phase 3 clinical trial or non-phased trials with greater than 300 subjects.	Clinical Trial with Planning Phase – All Funding Levels: • The maximum allowable funding for the entire period of performance is \$800,000 for total costs for Planning Phase.* • The maximum period of performance is 12 months. All Funding Levels: • The maximum period of performance is 4 years. Funding Level 1: • The maximum allowable funding for the entire period of performance is \$6.0 million (M) for total costs.* Funding Level 2: • The maximum allowable funding for the entire period of performance is \$10.0M for total costs.* Funding Level 3: • The maximum allowable funding for the entire period of performance is \$20.0M for total costs.*	Pre-Application (Preproposal): July 23, 2026 5:00 p.m. Eastern time Application: September 22, 2026 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Discovery Award Go to: - Program Announcement - General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPDA	Investigators at all career levels.	- Supports innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications with impact on one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. - Applications cannot support the logical progression of an already established line of questioning. - Applications must not include preliminary data. Clinical trials are not allowed. Submission of a letter of intent is required prior to full application submission.	- The maximum allowable funding for the entire period of performance is \$385,000 for total costs.* - The maximum period of performance is 2 years.	Pre-Application (Letter of Intent): July 16, 2026 5:00 p.m. Eastern time Application: July 30, 2026 11:59 p.m. Eastern time
Impact Award Go to: - Program Announcement - General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPIPA	Independent investigators at all career levels.	- Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research and insights from the real-world environment to foster clinical applicability. - Applications should demonstrate the potential to make a near-term, major impact on one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Partnering Principal Investigator (PI) Option: Supports meaningful and productive partnerships between two investigators, termed the initiating PI and partnering PI, collaborating on a single application. At least one PI must be a clinician researcher. Clinical trials are not allowed. Submission of a letter of intent is required prior to full application submission.	Single PI Option: - The maximum allowable funding for the entire period of performance is \$2.8M for total costs.* - The maximum period of performance is 4 years. Partnering PI Option: - The maximum allowable funding for the entire period of performance is \$3.6M for total costs.* - The maximum period of performance is 4 years.	Pre-Application (Letter of Intent): July 23, 2026 5:00 p.m. Eastern time Application: August 6, 2026 11:59 p.m. Eastern time
Lifestyle and Applied Health Research Award Go to: - Program Announcement - General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPLAHRA	Independent investigators at all career levels.	- Supports clinical research and/or clinical trials using a combination of scientific disciplines, including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health. - Applications must address and provide a solution to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. - Proposed projects may target the development of evidence-based practices, applied health science interventions, and the investigation of psychosocial patient outcomes. - Applications cannot support animal studies. Submission of a letter of intent is required prior to full application submission.	- The maximum allowable funding for the entire period of performance is \$4.2M for total costs.* - The maximum period of performance is 4 years.	Pre-Application (Letter of Intent): July 23, 2026 5:00 p.m. Eastern time Application: August 6, 2026 11:59 p.m. Eastern time

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Platform Clinical Translation Award Go to: - Program Announcement - General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPPCTA	Independent investigators at all career levels.	- Supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to <i>two FY26 PRMRP topic areas.</i> - Applications must address one of the FY26 PRMRP strategic goals. Partnering PI Option: Supports meaningful and productive partnerships between investigators, termed the initiating PI and partnering PI(s), collaborating on a single application. Applications allow up to two partnering PIs. <i>Preproposal submission is required; application submission is by invitation only.</i>	- The maximum allowable funding for the entire period of performance is \$15.0M for total costs.* - Only \$8.0M is currently available with FY26 funds; additional costs supported as optional research efforts. - The maximum period of performance is 4 years.	Pre-Application (Preproposal): July 23, 2026 5:00 p.m. Eastern time Application: September 22, 2026 11:59 p.m. Eastern time
Research Advancement Award Go to: - Program Announcement - General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPRAA	Independent investigators at all career levels.	- Supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. <i>Clinical trials are not allowed.</i> <i>Submission of a letter of intent is required prior to full application submission.</i>	- The maximum allowable funding for the entire period of performance is \$1.4M for total costs.* - The maximum period of performance is 4 years.	Pre-Application (Letter of Intent): July 16, 2026 5:00 p.m. Eastern time Application: July 30, 2026 11:59 p.m. Eastern time
Technology/Therapeutic Development Award Go to: - Program Announcement - General Application Instructions Grants.gov Funding Opportunity Number: HT942526PRMRPTTDA	Independent investigators at all career levels.	- Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. - Applications <i>must</i> describe product-oriented research. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. - Applications must include preliminary data demonstrating proof-of-concept for the product. <i>Clinical trials are not allowed.</i> <i>Submission of a letter of intent is required prior to full application submission.</i>	- The maximum allowable funding for the entire period of performance is \$5.6M for total costs.* - The maximum period of performance is 4 years.	Pre-Application (Letter of Intent): July 23, 2026 5:00 p.m. Eastern time Application: August 6, 2026 11:59 p.m. Eastern time

*Total costs include direct and indirect costs.